Skip to main content
Premium Trial:

Request an Annual Quote

Bruker's Q3 Revenues Rise 25 Percent; Tax-Law Changes Impact Bottom Line

NEW YORK (GenomeWeb News) - Bruker BioSciences today said third-quarter revenues increased 25 percent as R&D spending rose 24 percent and profit more than doubled.
 
Total receipts for the three months ended Sept. 30 increased 25 percent to $131.6 million from $104.9 million in the third quarter of 2006. Excluding the effects of foreign currency translation, third-quarter 2007 revenue increased by 20 percent, Bruker said.
 
Product revenue increased 25 percent to $115.2 million; service revenue increased 28 percent to $16.2 million; and "other" revenue fell 22 percent to $245,000.
 
The company did not offer revenue projections for the rest of the year.
 
R&D spending rose to $14.8 million from $11.9 million in the year-ago period.
 
Net profit rose to $8.7 million from $3 million in the year-ago period. The company said that income in the third quarter included a one-time tax benefit of $2.4 million related to a tax-law change in Germany that required a revaluation of Bruker’s deferred tax assets and liabilities.
 
Bruker held around $38.9 million in cash and cash equivalents, and short-term investments as of Sept. 30.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.